Literature DB >> 31255288

ORMDL3 knockdown in the lungs alleviates airway inflammation and airway remodeling in asthmatic mice via JNK1/2-MMP-9 pathway.

Huan Wang1, Ying Liu1, Jiang Shi1, Zhe Cheng2.   

Abstract

Orosomucoid-like protein 3 (ORMDL3) is a common mutation in many asthma patients and its effects on the specific pathogenesis of asthma are still unclear. Therefore, in this study, we used a mouse that specifically knockout the mouse ORDML3 gene to further study the mechanism. We used ovalbumin (OVA) to induce asthma in wild-type mice and ORMDL3 knockout mice. Lung ventilation resistance, airway inflammation, mucus hypersecretion, collagen deposition, the levels of inflammatory factors and the expression of ORDML3 and JNK1/2-MMP-9 pathway were detected. The results showed that ORMDL3 gene was highly expressed in clinical asthmatic children and mouse asthma model. Knocking down the ORMDL3 gene in the lung tissue of asthmatic mice can reduce airway hyperresponsiveness, airway inflammation, mucus secretion, and collagen deposition around the airway. After knocking down the lung tissue of mice, the IL-4, IL-5 and IL-13 concentrations in broncho alveolar lavage fluid of asthmatic mice were significantly decreased, and the activation of JNK1/2-MMP-9 pathway was inhibited in mouse lung tissue. Collectively, our results demonstrate that the ORMDL3 gene may aggravate asthma symptoms by activating the JNK1/2-MMP-9 pathway, which indicates that the ORMDL3 gene may be the key molecule for the next step of asthma targeted therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Airway remodeling; Asthma; Inflammation; Orosomucoid-like protein 3

Year:  2019        PMID: 31255288     DOI: 10.1016/j.bbrc.2019.06.122

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Sphingolipid Metabolism and Signaling in Endothelial Cell Functions.

Authors:  Linda Sasset; Annarita Di Lorenzo
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma.

Authors:  Tianbo Xu; Hailong Ruan; Su Gao; Jingchong Liu; Yuenan Liu; Zhengshuai Song; Qi Cao; Keshan Wang; Lin Bao; Di Liu; Junwei Tong; Jian Shi; Huageng Liang; Hongmei Yang; Ke Chen; Xiaoping Zhang
Journal:  Aging (Albany NY)       Date:  2020-01-30       Impact factor: 5.682

Review 3.  ORMDL3 and Asthma: Linking Sphingolipid Regulation to Altered T Cell Function.

Authors:  Christopher R Luthers; Teresa M Dunn; Andrew L Snow
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

4.  SIRT3 regulates bronchial epithelium apoptosis and aggravates airway inflammation in asthma.

Authors:  Jie Song; Jinxiang Wang
Journal:  Mol Med Rep       Date:  2022-03-02       Impact factor: 2.952

Review 5.  Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma.

Authors:  Zeyu Meng; Huize Chen; Chujun Deng; Shengxi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-16       Impact factor: 6.055

Review 6.  Role of microRNAs in type 2 diseases and allergen-specific immunotherapy.

Authors:  Constanze A Jakwerth; Hannah Kitzberger; Dimitrii Pogorelov; Annika Müller; Simon Blank; Carsten B Schmidt-Weber; Ulrich M Zissler
Journal:  Front Allergy       Date:  2022-09-12

7.  Curcumol Ameliorates Lung Inflammation and Airway Remodeling via Inhibiting the Abnormal Activation of the Wnt/β-Catenin Pathway in Chronic Asthmatic Mice.

Authors:  Shanshan Jia; Pin Guo; Junhua Lu; Xujun Huang; Laming Deng; Yan Jin; Lanyan Zhao; Xiaofang Fan
Journal:  Drug Des Devel Ther       Date:  2021-06-21       Impact factor: 4.162

Review 8.  Epithelial cell dysfunction, a major driver of asthma development.

Authors:  Irene H Heijink; Virinchi N S Kuchibhotla; Mirjam P Roffel; Tania Maes; Darryl A Knight; Ian Sayers; Martijn C Nawijn
Journal:  Allergy       Date:  2020-06-16       Impact factor: 13.146

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.